Cellectis S.A. Price, Forecast, Insider, Ratings, Fundamentals & Signals

Cellectis publishes an approach that could unlock new therapeutic avenues for the treatment of inborn metabolic diseases as well as neurological diseases

New york, april 08, 2024 (globe newswire) -- cellectis (the “company”) (euronext growth: alcls - nasdaq: clls), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, today announced that preliminary data exploring novel talen® editing process in hematopoietic stem and progenitor cells (hspcs) will be presented at the american society of gene and cell therapy (asgct) 27th annual meeting, to be held in baltimore, maryland, on may 7-11, 2024. poster presentations: title: circularization of non-viral single-strand dna template for gene correction and gene insertion improves editing outcomes in hspcs presenter: alex boyne, gene editing platform manager at cellectis session date/time: may 9, 2024 at 12pm et session title: nonviral therapeutic gene delivery and synthetic/molecular conjugates presentation room: exhibit hall final abstract number: 1235 cellectis presents the development of a novel gene editing process, leveraging the talen® technology and non-viral dna template delivery, enabling highly efficient gene correction and gene insertion in hematopoietic stem and progenitor cells (hspcs).

New york, jan. 16, 2024 (globe newswire) -- cellectis (euronext growth: alcls – nasdaq: clls) (the “company”), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, today announced that it has drawn down the second tranche of €15 million (“tranche b”) under the credit facility agreement for up to €40 million entered into with the european investment bank (the “eib) on december 28, 2022 (the "finance contract"). tranche b is expected to be disbursed by the eib by january 25, 2024. the company plans to use the proceeds of tranche b towards the development of its pipeline of allogeneic car t-cell product candidates: ucart22, ucart20x22, and ucart123.

New york, dec. 22, 2023 (globe newswire) -- cellectis (euronext growth: alcls; nasdaq: clls), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, held today a shareholders general meeting at 2:30 p.m. cet at the biopark auditorium, 11 rue watt, 4th floor, 75013 paris, france.

New york, nov. 17, 2023 (globe newswire) --  cellectis (euronext growth: alcls; nasdaq: clls), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, announced today that it will hold a general meeting on december 22, 2023 at 2:30 p.m. cet at the biopark auditorium, 11 rue watt, 4th floor, 75013 paris, france.

Cellectis SA (NASDAQ:CLLS ) Q3 2023 Earnings Conference Call November 7, 2023 8:00 AM ET Company Participants Arthur Stril - Chief Business Officer Andre Choulika - Co-founder, CEO& Director Mark Frattini - Chief Medical Officer Bing Wang - CFO Conference Call Participants Dev Prasad - Jefferies Hartaj Singh - Oppenheimer Jack Allen - Robert W. Baird & Co. Silvan Tuerkcan - JMP Securities Whitney Watson - Goldman Sachs Operator Good morning, everyone, and welcome to the Cellectis Third Quarter 2023 Earnings Calls.

Preliminary data from two early-stage studies are going to be shown at the ASH 2023 conference, showcasing its cell therapy candidates for non-Hodgkin lymphoma and B-cell acute lymphoblastic leukemia. The company recently entered into a collaboration agreement with AstraZeneca, receiving $245 million in cash and potential milestone payments for the development of up to 10 cell therapy candidates. Cellectis now has sufficient funds to run clinical trials for its candidates, including UCART20X22, UCART22, and UCART123, which are not part of the collaboration deal made with AstraZeneca.

NEW YORK, Nov. 02, 2023 (GLOBE NEWSWIRE) --  Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, announced today that preliminary results of the Phase I NATHALI-01 clinical trial evaluating UCART20x22 in patients with relapsed or refractory non-Hodgkin lymphoma (r/r NHL) and updated results of the Phase I BALLI-01 clinical trial evaluating UCART22 in patients with relapsed or refractory CD22+ B-cell acute lymphoblastic leukemia, (r/r B-ALL) will be presented at the American Society of Hematology 65th Annual Meeting (ASH 2023), that will take place on December 9-12, 2023 in San Diego (CA) and online.

NEW YORK, Nov. 01, 2023 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS- NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, today announced that it will report financial results for the third quarter ended September 30, 2023 on Monday, November 6, 2023 after the close of the US market.

Penny stocks are the wild west of the stock market. Fast-paced, unpredictable, and laden with potential treasures.

AstraZeneca said on Wednesday it had entered into a collaboration and investment agreement with clinical-stage biotechnology company Cellectis to speed up the development of therapeutics in areas including oncology and rare diseases.

NEW YORK, Oct. 24, 2023 (GLOBE NEWSWIRE) --  Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, announced today that they will be showcasing pre-clinical data on its program of gene therapy for HSPC as well as comprehensive analysis of TALE-BE editing determinants at the European Society of Gene and Cell Therapy (ESGCT) 30th annual congress that will take place on October 24-27, 2023 in Brussels, Belgium.

NEW YORK, Sept. 27, 2023 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, announced today that pre-clinical data on MUC1-CAR T-cells to overcome key challenges of targeting solid tumors, will be presented at the Society for Immunotherapy of Cancer's 38th Annual Meeting (SITC 2023), that will take place on November 1-5, 2023 at San Diego Convention Center in San Diego (CA).

Cellectis SA (NASDAQ:CLLS ) Q2 2023 Earnings Conference Call August 5, 2023 8:00 AM ET Company Participants Arthur Stril - Chief Business Officer Andre Choulika - Co-Founder, CEO & Director Mark Frattini - SVP, Clinical Sciences & Chief Medical Officer Bing Wang - CFO Conference Call Participants Yigal Nochomovitz - Citigroup Gena Wang - Barclays Bank Yanan Zhu - Wells Fargo Anoumid Vaziri - Goldman Sachs Group Dev Prasad - Jefferies Hartaj Singh - Oppenheimer Jack Allen - Robert W. Baird Silvan Tuerkcan - JMP Securities Operator Good morning, and everyone, welcome to Cellectis Second Quarter 2023 Earnings Call.

NEW YORK, July 27, 2023 (GLOBE NEWSWIRE) -- Cellectis S.A. (the “Company”) (Euronext Growth: ALCLS- NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, today announced that it will report financial results for the second quarter ended June 30, 2023 on Thursday, August 3, 2023 after the close of the US market.